Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentra intragastric injection for weight loss in adults with overweight or obesity
IRCT20150303021315N44Phase 4Completed
- Sponsor
- Espad Pharmed
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Lucentra in Overweight and obesity, sponsored by Espad Pharmed. Primary endpoint: Proportion of patients with at least 5% weight reduction. Started Sep 2026; status: completed.
02
Drugs
Lucentra
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on IRCT20150303021315N44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N44.